Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tilorone SCHEMBL30520073 | 1.00 | MAPT (1.00) | MAPTKMT2ACHRNA7POLBHTT | |
| Tilorone SCHEMBL29500271 | 1.00 | MAPT (1.00) | MAPTKMT2ACHRNA7POLBHTT | |
| Tilorone SCHEMBL30882955 | 0.98 | MAPT (0.97) | MAPTKMT2ACHRNA7POLBHTT | |
| Tilorone SCHEMBL30002597 | 0.98 | MAPT (0.97) | MAPTKMT2ACHRNA7POLBHTT | |
| Tilorone SCHEMBL11257327 | 0.98 | MAPT (0.97) | MAPTKMT2ACHRNA7POLBHTT | |
| Tilorone SCHEMBL146373 | 0.98 | MAPT (0.97) | MAPTKMT2ACHRNA7POLBHTT | |
| Tilorone SCHEMBL30882954 | 0.98 | MAPT (0.97) | MAPTKMT2ACHRNA7POLBHTT | |
| Tilorone SCHEMBL3701437 | 0.98 | MAPT (0.97) | MAPTKMT2ACHRNA7POLBHTT | |
| SCHEMBL146374 | 0.97 | MAPT (0.94) | MAPTKMT2ACHRNA7POLBHTT | |
| Tilorone SCHEMBL28965494 | 0.97 | MAPT (0.94) | MAPTKMT2ACHRNA7POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1098 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-12458622-B2 | Methods of treatment of coronavirus-induced inflammation conditions | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-04 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025137577-A1 | SHORT VIRAL RNAS (SVRNAS) WITH THERAGNOSTIC POTENTIAL IN INFECTION WITH SARS-COV-2 AND RELATED VIRUSES | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250186623-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| US-20250188143-A1 | COMBINED GENE AND RADIO THERAPY FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| WO-2025097070-A1 | ORAL DOSAGE FORM WITH CATIONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT | ENTREGA INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250134850-A1 | PLANT-DERIVED SMALL MOLECULES AS MARBURG VIRUS INHIBITORS | BAJRAI LEENA HUSSEIN (SA) | 2025-05-01 | — | — | US | claimed |
| EP-4525855-A1 | INTERCALATING SUGAR MOLECULES | Xalud Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250057819-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2025-02-20 | — | — | US | claimed |
| US-6080383-A | Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer | ROSE SAMUEL (US) | 2000-06-27 | — | — | US | claimed |
| WO-2000025787-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME | GUILFORD PHARMACEUTICALS INC. (US) | 2000-05-11 | — | — | WO | claimed |
| US-5816259-A | Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells | ROSE SAMUEL (US) | 1998-10-06 | — | — | US | claimed |
| WO-1998030247-A1 | A METHOD AND COMPOSITION FOR CANCER TREATMENT BY ENZYMATIC CONVERSION OF SOLUBLE RADIOACTIVE TOXIC AGENTS | ROSE SAMUEL (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0316440-B1 | System and method for providing localized Mössbauer absorption in an organic medium | MILLS RANDELL L (US) | 1996-01-03 | — | — | EP | claimed |
| EP-0525073-B1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | DU PONT (US) | 1994-05-25 | — | — | EP | claimed |
| EP-0525073-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. | DU PONT (US) | 1993-02-03 | — | — | EP | claimed |
| WO-1991015954-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-31 | — | — | WO | claimed |
| US-4455142-A | Method of coadministering an antigen and an immunopotentiator | ALZA CORPORATION (US) | 1984-06-19 | — | — | US | claimed |
| US-3947593-A | ANTIVIRUL AGENTS | RICHARDSON-MERRELL INC. (US) | 1976-03-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | MAPT 1647/4885KMT2A 1760/4885CHRNA7 83/4885 |
| US-12458622-B2 | Methods of treatment of coronavirus-induced inflammation conditions | C3AR1, IL5, IL4 | MAPT 4050/4885KMT2A 4447/4885CHRNA7 1726/4885 |
| US-20250057819-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | MME, ACE, ACE2 | MAPT 1710/4885KMT2A 4251/4885CHRNA7 483/4885 |
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | SLC2A1, SLC2A2, SLC2A4 | MAPT 4591/4885KMT2A 3581/4885CHRNA7 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.